CYTOGAM (Cytomegalovirus Immune Globulin) for CMV Prophylaxis After Transplantation
Customize your policy alerts
Sign up for all goldcoasthealthplan policy alerts
Know when goldcoasthealthplan releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization and Part B coverage of physician-administered CYTOGAM IV infusion for CMV disease prevention after kidney, lung, liver, pancreas, or heart transplantation, subject to specialist, dosing, administration-site, and duration requirements.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.